1. "Survivorship Research"
Formats
  1. Journal Article (8900)
  2. Meeting Abstract (5192)
  3. Book Section (571)
  4. Review (357)
  5. Editorial (225)
  6. Research Letter (132)
  7. Conference Paper (104)
  8. Correspondence (91)
  9. Guidelines (85)
  10. Miscellaneous (76)
  11. Book Whole (30)
Groups
  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (788)
  3. Michael Zelefsky (754)
  4. Sergio Giralt (684)
  5. Mark Robson (676)
  6. Joachim Yahalom (625)

More People

Years
  1. 2025 (231)
  2. 2024 (802)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (930)

More Years

Publications
  1. Journal of Clinical Oncology (1873)
  2. International Journal of Radiation Oncology, Biology, Physics (908)
  3. Blood (685)
  4. Annals of Surgical Oncology (599)
  5. Cancer Research (333)
  6. Cancer (331)

More Publications

Publishers
  1. Elsevier Inc. (2658)
  2. American Society of Clinical Oncology (2019)
  3. Springer (1542)
  4. Wiley Blackwell (806)
  5. Oxford University Press (787)
  6. American Society of Hematology (748)

More Publishers

Results (15763)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Opioid safety among older cancer survivors
    Meeting Abstract

    Salz, T.; Mishra, A.; Gennarelli, R.; Lipitz-Synderman, A.; Boudreau, D.; Moryl, N.; Tringale, K.; Korenstein, D.
    Medical Decision Making (2021)

    Fulltext@MSK | Save
  • Confused by international thyroid cancer guidelines?: TIRO (Thyroid International Recommendations Online) is here to help
    Meeting Abstract

    Rossleigh, M.; Pattison, D.; Tuttle, R. M.; Urken, M.; Gonzales-Velazquez, C.
    Internal Medicine Journal (2021)

    Fulltext@MSK | Save
  • Routine perioperative and post-discharge use of non-steroidal anti-inflammatory drugs: What is the risk of hematoma after lumpectomy and sentinel lymph node biopsy?
    Meeting Abstract

    Pawloski, K. R.; Matar, R.; Sevilimedu, V.; Tadros, A. B.; Kirstein, L.; Cody, H.; Van Zee, K.; Morrow, M.; Moo, T. A.
    Annals of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • The effect of age on outcomes after neoadjuvant chemotherapy for breast cancer
    Meeting Abstract

    Verdial, F. C.; Mamtani, A.; Pawloski, K. R.; Sevilimedu, V.; Gemignani, M.; Barrio, A. V.; Morrow, M.; Tadros, A. B.
    Annals of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
    Meeting Abstract

    Dang, C.; Ewer, M. S.; Delaloge, S.; Ferrero, J. M.; Colomer, R.; Merino, L. D.; Dadswell, K.; Verrill, M.; Eiger, D.; Sarkar, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1
    Meeting Abstract

    Rodon, J.; Demanse, D.; Rugo, H. S.; Andre, F.; Janku, F.; Mayer, I.; Burris, H.; Simo, R.; Farooki, A.; Hu, H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Textured and smooth implant use reported in the Tracking Operations and Outcomes for Plastic Surgeons database: Epidemiologic implications for BIA-ALCL
    Journal Article

    Matros, E.; Shamsunder, M. G.; Rubenstein, R. N.; Polanco, T. O.; McCarthy, C. M.; Nelson, J. A.; Gutowski, K.; the TOPS Steering Committee
    Plastic and Reconstructive Surgery-Global Open (2021)

    Fulltext@MSK | Save
  • Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy
    Journal Article

    Magbanua, M. J. M.; Hendrix, L. H.; Hyslop, T.; Barry, W. T.; Winer, E. P.; Hudis, C.; Toppmeyer, D.; Carey, L. A.; Partridge, A. H.; Pierga, J. Y.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Randomized phase II study of 3 months or 2 years of adjuvant afatinib in patients with surgically resected stage I-III EGFR-mutant non-small-cell lung cancer
    Journal Article

    Neal, J. W.; Costa, D. B.; Muzikansky, A.; Shrager, J. B.; Lanuti, M.; Huang, J.; Ramachandran, K. J.; Rangachari, D.; Huberman, M. S.; Piotrowska, Z.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Prevalence and characterization of biallelic and monoallelic NTHL1 and MSH3 variant carriers from a pan-cancer patient population
    Journal Article

    Salo-Mullen, E. E.; Maio, A.; Mukherjee, S.; Bandlamudi, C.; Shia, J. R.; Kemel, Y.; Cadoo, K. A.; Liu, Y.; Carlo, M.; Ranganathan, M.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save